These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

63 related articles for article (PubMed ID: 8118266)

  • 1. [Tumor biology-oriented treatment concepts].
    Graeff H; Wilhelm O; Jänicke F; Schmitt M
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():193-6. PubMed ID: 8118266
    [No Abstract]   [Full Text] [Related]  

  • 2. Study indicates utility for new breast cancer prognostic marker.
    Stephenson J
    JAMA; 2001 Jun; 285(24):3077-8. PubMed ID: 11427119
    [No Abstract]   [Full Text] [Related]  

  • 3. [Interview with private lecturer Dr. med. Nadia Harbeck, Munich. Prognostic markers guide therapy (interview by Jochen Aumiller)].
    Harbeck N
    MMW Fortschr Med; 2003 Jan; 145(3-4):8, 10. PubMed ID: 12619225
    [No Abstract]   [Full Text] [Related]  

  • 4. Dissemination risk index based on plasminogen activator system components in primary breast cancer.
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    J Clin Oncol; 1999 Oct; 17(10):3048-57. PubMed ID: 10506599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical relevance of prognostic factors in axillary node-negative breast cancer.
    Thomssen C; Jänicke F; Harbeck N
    Onkologie; 2003 Oct; 26(5):438-45. PubMed ID: 14605459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of urokinase-type plasminogen activator (PA), PA inhibitor type-1, and tissue-type PA antigen levels in node-negative breast cancer: a prospective study on multicenter basis.
    Kim SJ; Shiba E; Kobayashi T; Yayoi E; Furukawa J; Takatsuka Y; Shin E; Koyama H; Inaji H; Takai S
    Clin Cancer Res; 1998 Jan; 4(1):177-82. PubMed ID: 9516968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients.
    Borstnar S; Vrhovec I; Svetic B; Cufer T
    Clin Breast Cancer; 2002 Jun; 3(2):138-46. PubMed ID: 12123538
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1.
    Mengele K; Napieralski R; Magdolen V; Reuning U; Gkazepis A; Sweep F; Brünner N; Foekens J; Harbeck N; Schmitt M
    Expert Rev Mol Diagn; 2010 Oct; 10(7):947-62. PubMed ID: 20964613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
    Zheng MH; Fan Y; Panicker A; Smith A; Robertson T; Wysocki S; Robbins P; Papadimitriou JM; Wood DJ
    Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of urokinase-type plasminogen activator (uPA) and its type-1 inhibitor (PAI-1) for metastatic sentinel lymph node involvement in breast cancer.
    Harms W; Malter W; Krämer S; Drebber U; Drzezga A; Schmidt M
    Anticancer Res; 2014 Aug; 34(8):4457-62. PubMed ID: 25075085
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination.
    Harbeck N; Kates RE; Schmitt M
    J Clin Oncol; 2002 Feb; 20(4):1000-7. PubMed ID: 11844823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [DNA flow cytometric analysis in primary breast cancer. S-phase and ploidy status as prognostic factors and their correlation to tumor-associated proteolytic factors].
    Harbeck N; Schüren E; Yamamoto N; Pache L; Schmitt M; Jänicke F; Dettmar P; Höfler H; Graeff H
    Gynakol Geburtshilfliche Rundsch; 1993; 33 Suppl 1():303-4. PubMed ID: 8118325
    [No Abstract]   [Full Text] [Related]  

  • 13. [u-Plasminogen activator (urinary plasminogen activator, urokinase) (uPA) and its PA-1 type 1 inhibitor are not only prognostically but also predictively significant and support clinical decisions on therapy in primary carcinoma of the breast].
    Harbeck N; Thomssen C
    Zentralbl Gynakol; 2003 Sep; 125(9):362-7. PubMed ID: 14569518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [tPA, uPA, PAI-1 as prognostic factors of breast cancers].
    Shiba E; Kim SJ
    Nihon Rinsho; 2000 Apr; 58 Suppl():429-34. PubMed ID: 11026029
    [No Abstract]   [Full Text] [Related]  

  • 15. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Breast cancer: prognostic value of a dissemination index based on 4 components of the urokinase-type plasminogen activator system].
    Bouchet C; Hacène K; Martin PM; Becette V; Tubiana-Hulin M; Lasry S; Oglobine J; Spyratos F
    Pathol Biol (Paris); 2000 Nov; 48(9):825-31. PubMed ID: 11141918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Components of the Plasminogen-Plasmin System as Biologic Markers for Cancer.
    McMahon BJ; Kwaan HC
    Adv Exp Med Biol; 2015; 867():145-56. PubMed ID: 26530365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
    Marguet S; Mazouni C; Ramaekers BL; Dunant A; Kates R; Jacobs VR; Joore MA; Harbeck N; Bonastre J
    Eur J Cancer; 2016 Aug; 63():168-79. PubMed ID: 27322916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of measuring the prognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens.
    Thomssen C; Harbeck N; Dittmer J; Abraha-Spaeth SR; Papendick N; Paradiso A; Lisboa B; Jaenicke F; Schmitt M; Vetter M
    J Natl Cancer Inst; 2009 Jul; 101(14):1028-9. PubMed ID: 19535782
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.